SCHEMBL10293240

SCHEMBL10293240

CCNC(=O)c1cc2cc(S(=O)(=O)N3CCC(C)CC3)ccc2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
KDM4E B2RXH2 3/20 0.54
HSD17B10 Q99714 2/20 0.54
ALDH1A1 P00352 2/20 0.54
TSHR P16473 1/20 0.54
POLB P06746 1/20 0.53
RAB9A P51151 1/20 0.52
NAMPT P43490 2/20 0.52
MAPT P10636 4/20 0.51
LMNA P02545 3/20 0.50
MCOLN3 Q8TDD5 1/20 0.50
HTT P42858 1/20 0.50
BACE1 P56817 1/20 0.49
GAA P10253 1/20 0.48
RXFP1 Q9HBX9 1/20 0.47
THRB P10828 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10293124 0.88 KMT2A (0.61) MEN1KMT2AKDM4EHSD17B10ALDH1A1
SCHEMBL10293122 0.88 NAMPT (0.59) KDM4EHSD17B10ALDH1A1TSHRRAB9A
SCHEMBL10293175 0.88 NAMPT (0.47) ALDH1A1POLBRAB9ANAMPTMAPT
SCHEMBL10293140 0.87 LMNA (0.61) MEN1KMT2AKDM4EALDH1A1NAMPT
SCHEMBL8275562 0.86 KMT2A (0.52) MEN1KMT2AKDM4EHSD17B10ALDH1A1
SCHEMBL8276799 0.86 NPC1 (0.56) MEN1KMT2AKDM4EPOLBRAB9A
SCHEMBL10293113 0.85 KMT2A (0.58) MEN1KMT2AKDM4EHSD17B10ALDH1A1
SCHEMBL10293180 0.84 KMT2A (0.60) MEN1KMT2AKDM4EHSD17B10ALDH1A1
SCHEMBL10293200 0.84 MEN1 (0.59) MEN1KMT2AKDM4EHSD17B10POLB
SCHEMBL8276708 0.84 ALDH1A1 (0.52) MEN1KMT2AKDM4EHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211935-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-03 US disclosed
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C MEN1 3121/4885KMT2A 3808/4885KDM4E 3067/4885
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C MEN1 3121/4885KMT2A 3808/4885KDM4E 3067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.